The study identifies Barrett’s esophagus, colorectal lesions, inflammatory bowel disease, pancreatic cysts, biliopancreatic strictures and gastric diseases as conditions that could be benefit from the use of Cellvizio.
The technology form Mauna Kea hold both FDA 510(k) clearance and a European CE Mark.
More articles on gastroenterology:
Zacks reiterates Boston Scientific’s “neutral” rating
23 gastroenterologists making headlines
Smoking increases mortality risk in colorectal cancer patients
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
